← TrialMatch
HomeTrials

Olfactory Testing in Perinatal Asphyxia: Enhancing Risk Assessment

Neonatal asphyxia remains a leading cause of neurodevelopmental disabilities despite advancements in perinatal care. Hypoxic-ischemic encephalopathy (HIE), a severe outcome of asphyxia, impacts 1-3 infants per 1,000 live births annually in industrialized nations, causing long-term neurological impairments such as cogni

Condition(s)Mild Birth Asphyxia, Moderate Birth Asphyxia
StatusRecruiting
Study typeObservational
SummaryNeonatal asphyxia remains a leading cause of neurodevelopmental disabilities despite advancements in perinatal care. Hypoxic-ischemic encephalopathy (HIE), a severe outcome of asphyxia, impacts 1-3 infants per 1,000 live births annually in industrialized nations, causing long-term neurological impairments such as cognitive dysfunction, motor deficits, and sensory impairments. Early identification of at-risk newborns is critical to initiate timely interventions and improve outcomes. Olfactory perception, crucial for newborns' adaptation to extrauterine life, involves odor identification and memory. Odor perception is known to be impaired in adults with neurological disorders and in animal models of brain injury. However, no clinical studies have assessed olfactory function in newborns with
Who can participateInclusion Criteria: * Term newborns (37-41 weeks of gestational age) with signs of asphyxia at birth (cord pH \< 7.10 and/or BE \> -12). * Maternal age \> 18 years. * No medication use during pregnancy (e.g., antipsychotics, antidepressants, sedatives, anticonvulsants, anxiolytics). * Absence of maternal infections. * Apgar score \< 5 at 10 minutes of life. * Newborns with mild asphyxia at birth. * Newborns with moderate asphyxia at birth, at risk of developing hypoxic-ischemic encephalopathy, who don't need hypothermia treatment. * Newborns with severe asphyxia at birth, at risk of developing hypoxic-ischemic encephalopathy who don't need hypothermia treatment. Exclusion Criteria: * Post-term infants (gestational age \> 42 weeks). * Preterm infants (gestational age \< 37 weeks). * Infants
Ages6 Hours to 72 Hours
SexAll
Lead sponsorUniversity of Parma
LocationsParma, Italy
Start date2024-09-10
NCT IDNCT06744244
Official listinghttps://clinicaltrials.gov/study/NCT06744244

🔍 Search all trials →